TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
scPharmaceuticals ( (SCPH) ) just unveiled an announcement.
On August 20, 2025, scPharmaceuticals Inc. amended its supply agreement with West Pharmaceutical Services, Inc. for the SmartDose® drug delivery system, extending the agreement’s term until December 31, 2027. The amendment outlines the company’s financial responsibilities upon termination, impacting its operational commitments and strategic partnerships in the drug delivery market.
The most recent analyst rating on (SCPH) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on scPharmaceuticals stock, see the SCPH Stock Forecast page.
Spark’s Take on SCPH Stock
According to Spark, TipRanks’ AI Analyst, SCPH is a Neutral.
scPharmaceuticals’ overall stock score is primarily influenced by its financial instability, marked by high debt levels and negative cash flows. Despite strong revenue growth and strategic advancements highlighted in the earnings call, the company’s valuation challenges and mixed technical indicators contribute to a lower score. The focus on improving financial health and operational efficiency remains crucial for future stability.
To see Spark’s full report on SCPH stock, click here.
More about scPharmaceuticals
scPharmaceuticals Inc. operates in the pharmaceutical industry, focusing on the development and commercialization of innovative drug delivery systems.
Average Trading Volume: 318,245
Technical Sentiment Signal: Buy
Current Market Cap: $258.5M
Learn more about SCPH stock on TipRanks’ Stock Analysis page.